| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2685 | 2019 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1690 | 2012 |
| Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin A Levin, CR Thompson, J Ethier, EJF Carlisle, S Tobe, D Mendelssohn, ... American Journal of Kidney Diseases 34 (1), 125-134, 1999 | 1340 | 1999 |
| Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children KA Nerenberg, KB Zarnke, AA Leung, K Dasgupta, S Butalia, K McBrien, ... Canadian Journal of Cardiology 34 (5), 506-525, 2018 | 751 | 2018 |
| Guidelines for the management of chronic kidney disease A Levin, B Hemmelgarn, B Culleton, S Tobe, P McFarlane, M Ruzicka, ... Cmaj 179 (11), 1154-1162, 2008 | 657 | 2008 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 618 | 2019 |
| Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children DM Rabi, KA McBrien, R Sapir-Pichhadze, M Nakhla, SB Ahmed, ... Canadian Journal of Cardiology 36 (5), 596-624, 2020 | 608 | 2020 |
| The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis M Roerecke, J Kaczorowski, SW Tobe, G Gmel, OSM Hasan, J Rehm The Lancet Public Health 2 (2), e108-e120, 2017 | 581 | 2017 |
| Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of … AA Leung, K Nerenberg, SS Daskalopoulou, K McBrien, KB Zarnke, ... Canadian Journal of Cardiology 32 (5), 569-588, 2016 | 581 | 2016 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 566 | 2019 |
| Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10 UI Scholl, M Choi, T Liu, VT Ramaekers, MG Häusler, J Grimmer, ... Proceedings of the National Academy of Sciences 106 (14), 5842-5847, 2009 | 511 | 2009 |
| The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension SS Daskalopoulou, DM Rabi, KB Zarnke, K Dasgupta, K Nerenberg, ... Canadian Journal of Cardiology 31 (5), 549-568, 2015 | 503 | 2015 |
| Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults AA Leung, SS Daskalopoulou, K Dasgupta, K McBrien, S Butalia, ... Canadian Journal of Cardiology 33 (5), 557-576, 2017 | 457 | 2017 |
| Measurement of blood pressure in the office: recognizing the problem and proposing the solution MG Myers, M Godwin, M Dawes, A Kiss, SW Tobe, J Kaczorowski Hypertension 55 (2), 195-200, 2010 | 398 | 2010 |
| The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension K Dasgupta, RR Quinn, KB Zarnke, DM Rabi, P Ravani, ... Canadian Journal of Cardiology 30 (5), 485-501, 2014 | 392 | 2014 |
| Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial MG Myers, M Godwin, M Dawes, A Kiss, SW Tobe, FC Grant, ... Bmj 342, 2011 | 362 | 2011 |
| Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter A Levin, O Djurdjev, B Barrett, E Burgess, E Carlisle, J Ethier, K Jindal, ... American Journal of kidney diseases 38 (6), 1398-1407, 2001 | 344 | 2001 |
| The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy D De Zeeuw, B Coll, D Andress, JJ Brennan, H Tang, M Houser, ... Journal of the American Society of Nephrology 25 (5), 1083-1093, 2014 | 332 | 2014 |
| The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2–therapy DG Hackam, NA Khan, BR Hemmelgarn, SW Rabkin, RM Touyz, ... Canadian Journal of Cardiology 26 (5), 249-258, 2010 | 326 | 2010 |
| The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension DG Hackam, RR Quinn, P Ravani, DM Rabi, K Dasgupta, ... Canadian Journal of Cardiology 29 (5), 528-542, 2013 | 309 | 2013 |
NRC CampbellProfessor Emeritus University of CalgaryE-mailová adresa ověřena na: ucalgary.ca
